Merck's America's Diabetes Challenge: Get to Your Goals campaign is aimed at persuading patients to do what it takes to keep their blood sugar in check. Now, Merck is launching a similar campaign aimed at the Hispanic community, which is disproportionately affected by the disease.
Scientists have linked a single enzyme to the development of diabetes, a finding that could help develop new treatments for the more than 120 million Americans that have diabetes or pre-diabetes.
Without the safety concerns that plague its competitors, Jardiance may be able to make a splash.
Investigators at The Scripps Research Institute discovered a signaling pathway that switches on a calorie-burning phenomenon in cells.
The FDA is changing its tune on Jardiance, a Boehringer Ingelheim diabetes med it hasn't been so keen on in the past. After rejecting the drug in the face of a manufacturing issue, the agency Friday gave it approval to treat Type 2 diabetes.
According to an internal memo obtained by The Wall Street Journal blog Pharmalot, Whitaker is leaving for "another opportunity."
A committee of European Medicines Agency advisers is recommending approval for Novo Nordisk's combination of a long-acting insulin and its blockbuster GLP-1 drug Victoza, setting the stage for a near-term approval of what's expected to be the diabetes giant's next big therapy.
The pharma sector in India is reeling after the National Pharmaceutical Pricing Authority said it's capping prices on about 100 drugs to treat diabetes and heart disease. And the company that could suffer most isn't India-based.
A chemical compound designed by researchers at the University of California, San Francisco, protected mice and rats against degenerative forms of blindness and diabetes by targeting a central stress response area.
Across three Phase III trials, Sanofi's in-development replacement for Lantus was better at battling low blood sugar than the company's cash cow insulin product, providing hope for the drugmaker's diabetes business when its blockbuster goes off patent next year.